Characterization of acute and delayed ocular lesions induced by sulfur mustard in rabbits.
OBJECTIVE
To establish an experimental model for sulfur mustard-induced acute and delayed ocular lesions in rabbits.


METHODS
Rabbit eyes were exposed to sulfur mustard (HD) vapor (370, 420 microg/l) for a period of two minutes. A three months follow-up study was carried out, based on the evaluation of clinical, biochemical and histological parameters.


RESULTS
HD exposure initiated typical clinical symptoms within 2-6 hrs, characterized by eye closure, eyelid swelling, conjunctival hyperemia, corneal erosions and inflammation. The clinical signs were significantly dose-dependent and reached a peak at 24--72 hrs post exposure. Biochemical evaluation of the aqueous humor exhibited an inflammatory reaction and oxidative stress at 4 hrs after exposure, subsiding at 28 hrs after exposure. Histological examination of corneas at 48 hrs revealed epithelial denudation and marked stromal edema, accompanied by cellular infiltration. Epithelial regeneration started after 72 hrs, and recovery was almost completed within 1--2 weeks, depending on the HD dose. A second phase of pathological processes started as early as two weeks post exposure and was characterized by corneal edema, opacity, recurrent erosions and neovascularization. The delayed injuries were found in 25 and 40% of the eyes respectively, and when appearing, were more severe than the initial ones.


CONCLUSIONS
The development of HD-induced ocular lesions in rabbits is similar to the lesions described in human casualties. Quantitative analysis of the various clinical parameters emphasizes the contribution of each tissue to the overall toxic picture. Our experimental model is useful for studying the pathological mechanisms of HD-ocular lesions, and may serve for testing potential therapies.
Kadar
T
T
Department of Pharmacology, Israel Institute for Biological Research, Ness-Ziona, Israel. kadar@iibr.gov.il
Turetz
J
J
Fishbine
E
E
Sahar
R
R
Chapman
S
S
Amir
A
A
D000208:Acute Disease; D000818:Animals; D001205:Ascorbic Acid / Q000378:metabolism; D003315:Cornea / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D015715:Corneal Edema / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D016510:Corneal Neovascularization / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D003318:Corneal Opacity / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D003879:Dermatologic Agents / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005136:Eye Proteins / Q000378:metabolism; D005260:Female; D005978:Glutathione / Q000378:metabolism; D023421:Models, Animal; D009151:Mustard Gas / Q000633:toxicity*; D011817:Rabbits; D013997:Time Factors
D003879:Dermatologic Agents; D005136:Eye Proteins; D005978:Glutathione; D001205:Ascorbic Acid; D009151:Mustard Gas